Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 8/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31317984 | 0.97 | ALB (0.45) | ALBPOLBTDP1CA1CA2 | |
| SCHEMBL31318002 | 0.95 | ALB (0.41) | ALBPOLBTDP1CA1CA2 | |
| SCHEMBL31317985 | 0.93 | POLB (0.40) | ALBPOLBTDP1CA1CA2 | |
| SCHEMBL31317941 | 0.89 | POLB (0.41) | POLBTDP1CA1CA2ATM | |
| SCHEMBL19743079 | 0.88 | ALB (0.52) | ALBFOLH1 | |
| SCHEMBL19743081 | 0.88 | ALB (0.52) | ALBFOLH1 | |
| SCHEMBL19743137 | 0.85 | ALB (0.48) | ALBFOLH1 | |
| SCHEMBL19743136 | 0.85 | ALB (0.48) | ALBFOLH1 | |
| SCHEMBL19743134 | 0.84 | FOLH1 (0.50) | ALBFOLH1 | |
| SCHEMBL19743135 | 0.84 | FOLH1 (0.50) | ALBFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091008-A1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | CORNELL UNIVERSITY (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4520745-A2 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | Cornell University (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-3474903-B1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | UNIV CORNELL (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12186288-B2 | Double targeted constructs to affect tumor kill | CORNELL UNIVERSITY (US) | 2025-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091008-A1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | PSMA2, CD47, KLK3 | ALB 1858/4885POLB 2833/4885TDP1 2617/4885 |
| US-12186288-B2 | Double targeted constructs to affect tumor kill | PSMA2, FOLH1, KLK3 | ALB 1812/4885POLB 1548/4885TDP1 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.